Nurofen 200mg Coated Tablets
*Company:
Reckitt Benckiser Ireland LimitedStatus:
No Recent UpdateLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 25 September 2024
File name
IE PIL Nurofen 200mg Tabs CRN00F0DT PRAC 10 July2024.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 4 - possible side effects
Updated on 25 September 2024
File name
IE Nurofen 200mg Tab SmPC CRN00F0DT App July 2024 PRAC 10.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Supply through pharmacy only
Updated on 10 April 2024
File name
IE PIL NUROFEN 200mg Tablets Clean CRN00DDJT PRAC 7.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 10 April 2024
File name
SPC Nurofen 200mg Tablets Clean CRN00DDJT PRAC 7.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
Legal category:Supply through pharmacy only
Updated on 23 October 2021
File name
Nurofen 200mg Tabs PIL Apr21.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 23 October 2021
File name
Nurofen 200mg Tablets SmPC Apr21.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Supply through pharmacy only
Updated on 02 April 2020
File name
IE SPC Nurofen 200mg Tablets Mar 2020.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Supply through pharmacy only
Updated on 02 April 2020
File name
200mg Coated Tablets.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 15 January 2020
File name
Nurofen 200 mg Coated Tablets.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 16 August 2017
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 16 August 2017
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.4 and 4.8- chicken Pox warning
Section 10 - revision of text update
Updated on 15 August 2017
File name
PIL_12698_910.pdf
Reasons for updating
- New PIL for new product
Updated on 15 August 2017
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
Updated on 10 October 2014
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 07 October 2014
Reasons for updating
- Change to warnings or special precautions for use
- Change to dosage and administration
Updated on 04 March 2014
Reasons for updating
- Change due to harmonisation of SPC
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 03 March 2014
Reasons for updating
- Change due to harmonisation of PIL
Updated on 15 March 2012
Reasons for updating
- Change to section 6.1 - List of excipients
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Black Printing Ink
(iron oxide black (E172), propylene glycol (E1520), shellac)
Updated on 14 March 2012
Reasons for updating
- Change due to user-testing of patient information
Updated on 13 October 2011
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 6.1 - List of excipients
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
For a full list of excipients, see section 6.1.
Section 6.1 - to divide the list of excipients into tablet core and tablet coat
Updated on 12 October 2011
Reasons for updating
- Change to improve clarity and readability
Updated on 21 May 2009
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.5 new information added -
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelets aggregation when they are dosed concomitantly. However, the limitations of these data and the uncertainties regarding the extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional use (see section 5.1)
Section 5.1 new information added
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelets aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400mg was taken within 8 h before or within 30 min after immediate release aspirin (81mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.
Updated on 21 May 2009
Reasons for updating
- Change to drug interactions
Updated on 10 December 2007
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Addition of NSAID warnings to sections 4.3, 4.4, 4.5 and 4.8 of the SPC
Updated on 10 December 2007
Reasons for updating
- Change of inactive ingredient
Updated on 04 December 2007
Reasons for updating
- New PIL for medicines.ie
Updated on 27 August 2007
Reasons for updating
- New SPC for medicines.ie
Legal category:Supply through pharmacy only